| Name | Title | Contact Details |
|---|
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
Kyowa Kirin North America is a fully integrated specialty pharmaceutical company, where people work together to understand clinical needs and opportunities for innovation that can result in real advances for patients. Since 2018, the North American organization has received approval from the US Food and Drug Administration (FDA) to market 3 first-in-class medicines – achievements we share with the scientific, medical, and advocacy communities who contributed greatly to the success of these programs.
Yusef Manufacturing Labs is a Kaysville, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Paramount Pharmacies Limited is a New Waterford, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Saluda Medical is a global medical device company focused on patient outcomes, science, and engineering to transform the neuromodulation industry with a platform of closed-loop technologies that optimize therapy by reading, recording, and responding to the nerves' response to stimulation` The company's first product, Evoke®, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system designed to treat chronic pain, a condition that affects more than 540 million people globally` SCS treats the condition by stimulating the spinal cord and altering the transmission of pain signals to the brain` Saluda's proprietary Evoke System is the only closed-loop SCS system designed to maintain individualized, consistent therapy by precisely controlling spinal cord activation through real-time customization of waveforms on every evoked compound action potential (ECAP) at the same rate as the stimulation frequency (At stimulation frequency of 40 Hz, 40 adjustments are made each second, 3`5 million adjustments per day, and 1`2 billion adjustments per year)`